Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
But Perspective sinks again.
